BioWorld Asia

Sep. 23, 2009

Pieris Getting $10M Up Front in Allergan Ophthalmology Deal

Pieris AG is getting an up-front payment of $10 million from Allergan Inc., as part of a licensing deal under which the latter firm will gain access to its anticalin technology in ophthalmology indications. (BioWorld International) Read More

Wellcome Trust, Merck Team Up to Create £90M Vaccine Program

New Tools to Allow Deeper Scrutiny of Cancer-Fighting Cells

After Rebuffing Potential Suitor, Renovo Slashes Staffing, R&D

Cell Medica Raises £1.95M to Expand Cell Therapy Work

Signaling Systems the Focus on $22M Push in Systems Biology

AGI Therapeutics' New Strategy: Extending into Niche Markets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...